Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
semaglutide
- Development stage
- Approved
- Lead developer
- Novo Nordisk
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Oral
01
Overview
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the treatment of type 2 diabetes, chronic weight management in obesity or overweight adults with at least one weight-related comorbidity, and to reduce the risk of major adverse cardiovascular events in certain populations. It works by mimicking endogenous GLP-1 to stimulate insulin secretion, suppress glucagon release, delay gastric emptying, and reduce appetite. Semaglutide is available as a once-weekly subcutaneous injection (Ozempic and Wegovy) or as a daily oral tablet (Rybelsus). Developed by Novo Nordisk, it was first approved for type 2 diabetes in 2017 and later for chronic weight management[1][3][5][7].
- Brand names
- OzempicWegovyRybelsus
- Other names
- semaglutide subcutaneoussemaglutide injection (HD1916)
02
Targets
Beyond the preview
Go deeper on semaglutide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on semaglutide.